nafamostat has been researched along with Systemic Inflammatory Response Syndrome in 5 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Systemic Inflammatory Response Syndrome: A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever
| Excerpt | Relevance | Reference |
|---|---|---|
| " "In vivo" generation of neutrophil-activating factors by gut proteases may be a cause of multiorgan failure after hemorrhagic shock, and can be prevented with the serine protease inhibitor nafamostat mesilate (Futhan)." | 7.72 | Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock. ( Coimbra, R; Doucet, JJ; Hoyt, DB; Hugli, TE; Junger, WG; Loomis, WH; Paul L, W; Schmid-Schönbein, GW, 2004) |
| " "In vivo" generation of neutrophil-activating factors by gut proteases may be a cause of multiorgan failure after hemorrhagic shock, and can be prevented with the serine protease inhibitor nafamostat mesilate (Futhan)." | 3.72 | Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock. ( Coimbra, R; Doucet, JJ; Hoyt, DB; Hugli, TE; Junger, WG; Loomis, WH; Paul L, W; Schmid-Schönbein, GW, 2004) |
| "Whereas in DIC associated with trauma, since balance between coagulation and fibrinolysis collapses drastically in a short period, both anticoagulantion therapy and antifibrinolytic therapy can be utilized depending on clinical conditions." | 2.53 | [Anti DIC therapy]. ( Sakamoto, Y; Yahata, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yahata, M | 1 |
| Sakamoto, Y | 1 |
| Kim, HD | 1 |
| Malinoski, DJ | 1 |
| Borazjani, B | 1 |
| Patel, MS | 1 |
| Chen, J | 1 |
| Slone, J | 1 |
| Nguyen, XM | 1 |
| Steward, E | 1 |
| Schmid-Schonbein, GW | 2 |
| Hoyt, DB | 2 |
| Kaminishi, Y | 1 |
| Hiramatsu, Y | 1 |
| Watanabe, Y | 1 |
| Yoshimura, Y | 1 |
| Sakakibara, Y | 1 |
| Doucet, JJ | 1 |
| Coimbra, R | 1 |
| Junger, WG | 1 |
| Paul L, W | 1 |
| Loomis, WH | 1 |
| Hugli, TE | 1 |
| Kitagawa, H | 1 |
| Tani, T | 1 |
| Takamura, H | 1 |
| Kayahara, M | 1 |
| Ohta, T | 1 |
2 reviews available for nafamostat and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
[Anti DIC therapy].
Topics: Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzamidines; Disseminated Intravascular Coa | 2016 |
[Quality of life in surgical treatment of pancreatic cancer].
Topics: Benzamidines; Drainage; Guanidines; Humans; Lymph Node Excision; Pancreatectomy; Pancreatic Neoplasm | 2006 |
1 trial available for nafamostat and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Topics: Aged; Aprotinin; Benzamidines; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Drug Therap | 2004 |
2 other studies available for nafamostat and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Inhibition of intraluminal pancreatic enzymes with nafamostat mesilate improves clinical outcomes after hemorrhagic shock in swine.
Topics: Analysis of Variance; Animals; Benzamidines; Disease Models, Animal; Drug Evaluation, Preclinical; D | 2010 |
Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
Topics: Animals; Benzamidines; Blood Transfusion; Electrolytes; Enema; Guanidines; Intestinal Mucosa; Intest | 2004 |